← Human Trials & Peer-Reviewed Studies
A randomized comparison of methylene blue-directed biopsy versus conventional four-quadrant biopsy for the detection of intestinal metaplasia and dysplasia in patients with long-segment Barrett's esophagus
Plain-language guide to PMID 17970838 (2008): crossover randomized controlled trial study of Methylene blue (non-peptide stack partner) in 48 patients.
Key Facts
- PMID
- 17970838
- Journal
- The American journal of gastroenterology
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Horwhat JD et al. (7 authors)
- DOI
- 10.1111/j.1572-0241.2007.01601.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).
Methylene blue (MB) selectively stains specialized intestinal metaplasia (SIM) and may assist in surveying a columnar-lined esophagus for Barrett's esophagus associated dysplasia.
Their aim was to correlate stain intensity with histology.
Who Took Part
The study group was 48 patients.
The age groups tagged for this paper are middle-aged adults, both men and women.
This is a prospective, randomized crossover study comparing 4-quadrant random biopsies (4QB) versus MB-directed biopsies for the detection of SIM and dysplasia in 48 patients with long segment Barrett's esophagus (LSBE).
Patients randomly underwent two endoscopies over a 4-wk time period with either 4QB or MB-directed biopsies as their first or second exam.
How the Study Was Run
The researchers set it up as a randomized and crossover study.
The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.
In the crossover set-up each of the patients took both Methylene blue (non-peptide stack partner) and the comparison in turn, acting as their own control.
What Was Measured
PubMed files the paper under topics including Barrett Esophagus, Biopsy, Needle, Coloring Agents, Epithelium, Esophagoscopy, Esophagus and Metaplasia.
What This Means in Plain Language
The paper is a randomized and crossover study of Methylene blue (non-peptide stack partner) in 48 patients.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2008 (The American journal of gastroenterology), a journal based in United States.
More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.